MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.

The earliest recognizable atherosclerotic lesions are fatty streaks composed of lipid-laden macrophages (foam cells). Circulating monocytes are the precursors of these foam cells, but the molecular mechanisms that govern macrophage trafficking through the vessel wall are poorly understood. Monocyte chemoattractant protein-1 (MCP-1), a member of the chemokine (chemotactic cytokine) family, is a potent monocyte agonist that is upregulated by oxidized lipids. Recent studies in hypercholesterolemic mice lacking apo E or the low-density lipoprotein receptor have suggested a role for MCP-1 in monocyte recruitment to early atherosclerotic lesions. To determine if MCP-1 is critically involved in atherogenesis in the setting of elevated physiological plasma cholesterol levels, we deleted the MCP-1 gene in transgenic mice expressing human apo B. Here we report that the absence of MCP-1 provides dramatic protection from macrophage recruitment and atherosclerotic lesion formation in apo B transgenic mice, without altering lipoprotein metabolism. Taken together with the results of earlier studies, these data provide compelling evidence that MCP-1 plays a critical role in the initiation of atherosclerosis.

[1]  S. Young,et al.  Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. , 1999, Journal of lipid research.

[2]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[3]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[4]  S. Young,et al.  Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Hogan,et al.  Altered wound healing in mice lacking a functional osteopontin gene (spp1). , 1998, The Journal of clinical investigation.

[6]  S. Young,et al.  Genetically modified mice for the study of apolipoprotein B. , 1998, Journal of lipid research.

[7]  S. Young,et al.  Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene. , 1998, The Journal of clinical investigation.

[8]  H. Shizuya,et al.  Human Apolipoprotein B Transgenic Mice Generated with 207- and 145-Kilobase Pair Bacterial Artificial Chromosomes , 1997, The Journal of Biological Chemistry.

[9]  S. Young,et al.  Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. , 1997, The Journal of clinical investigation.

[10]  S. Young,et al.  Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Huie,et al.  RANTES chemokine expression in transplant-associated accelerated atherosclerosis. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  I. Goldberg.  Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. , 1996, Journal of lipid research.

[13]  E M Rubin,et al.  Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. , 1995, Journal of lipid research.

[14]  M. Callow,et al.  Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). , 1995, The Journal of clinical investigation.

[15]  Robert V Farese,et al.  Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. , 1995, The Journal of clinical investigation.

[16]  Robert V Farese,et al.  Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Ross,et al.  Cell biology of atherosclerosis. , 1995, Annual review of physiology.

[18]  E. Rubin,et al.  Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. , 1994, Journal of lipid research.

[19]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[20]  D K Burns,et al.  Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. , 1994, The Journal of clinical investigation.

[21]  N. Maeda,et al.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[22]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  Robert V Farese,et al.  Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). , 1993, The Journal of clinical investigation.

[24]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[25]  D. Adams,et al.  Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[27]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[28]  A. J. Valente,et al.  Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  N. Maeda,et al.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. G. Brown,et al.  From familial combined hyperlipidemia to hyperapob: unravelling the overproduction of hepatic apolipoprotein B , 1992 .

[31]  D. Steinberg,et al.  Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Coughlin,et al.  Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.

[33]  D. Steinberg,et al.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Krauss,et al.  Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. J. Valente,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Paigen,et al.  Synthetic low and high fat diets for the study of atherosclerosis in the mouse. , 1990, Journal of lipid research.

[37]  R. Williams,et al.  Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.

[38]  S. Young,et al.  Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. , 1986, Clinical chemistry.

[39]  A. Sniderman,et al.  Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. , 1986, The Journal of clinical investigation.

[40]  S. Young,et al.  Conservation of the Low Density Lipoprotein Receptor‐Binding Domain of Apoprotein B , 1986, Arteriosclerosis.

[41]  S. Young,et al.  Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Paigen,et al.  Variation in susceptibility to atherosclerosis among inbred strains of mice. , 1985, Atherosclerosis.

[43]  R. Ross,et al.  Studies of Hypercholesterolemia in the Nonhuman Primate: I. Changes that Lead to Fatty Streak Formation , 1984, Arteriosclerosis.

[44]  Gerrity Rg.  The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. , 1981 .

[45]  R. Gerrity.  The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. , 1981, The American journal of pathology.

[46]  S. Shapiro,et al.  Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. , 1980, Proceedings of the National Academy of Sciences of the United States of America.